Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 45 sec. here
  • 8 min. at publisher
  • 📊 Quality Score:
  • News: 42%
  • Publisher: 63%

Novo Nordisk News

Eli Lilly,Amgen,Market Leaders

Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.

) positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday.

Eli Lilly CEO David Ricks similarly noted that it was really a matter of making the right moves to maintain the market lead.Both companies have early-stage next-generation products in the pipeline in addition to the clinical trials for expanded uses of current products. Louis Gossett Jr. fought a years-long battle with the disease but died on March 29, according to a family member.Killer TD variable rate mortgage could be sign of better deals to come

"Being really open about quite personal things I think is really important," the actress said at the King's Trust Gala on May 2You can expect to earn reliable monthly passive income for years to come by investing in these two top Canadian monthly dividend stocks now. The post Monthly Income Masters: 2 Canadian Stocks Paying Steady Dividends Every 30 Days appeared first on The Motley Fool Canada.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 47. in BUSÄ°NESS
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Business Business Latest News, Business Business Headlines